Phosphodiesterase type 5 inhibitors and kidney disease.

Abstract

Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors' utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin-angiotensin system blockade.

• Authors: Baris Afsar, Alberto Ortiz, Adrian Covic, Abduzhappar Gaipov, Tarik Esen, David Goldsmith, Mehmet Kanbay
• Journal: International urology and nephrology (Int Urol Nephrol) Vol. 47 Issue 9 Pg. 1521-8 (Sep 2015) ISSN: 1573-2584 [Electronic] Netherlands
• PMID: 26242375 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Phosphodiesterase 5 Inhibitors

Topics

• Disease Progression
• Humans
• Phosphodiesterase 5 Inhibitors (therapeutic use)
• Renal Insufficiency, Chronic (drug therapy, metabolism)
• Renin-Angiotensin System (drug effects)